Natco Pharma चुनौतियों से जूझती उम्मीद, अनुसंधान की ताकत और गुणवत्ता के प्रति प्रतिबद्धता के साथ, निवेशकों के धैर्य और समझदारी के सफर में असली साथी।

Technical Chart Analysis Natco Pharma remains in a sustained downtrend as seen on the daily chart, where price is trading below all major moving averages including 20, 50, 100, and 200 DMA. Parabolic SAR dots continue to appear above daily price candles, indicating persistent selling pressure. MACD is firmly in negative territory and RSI is at 46, which suggests the stock is not oversold but still lacks buying strength. Attempts at short-term rebounds have failed near 20/50 DMA resistance zones, and the structure remains weak. Most oscillators and moving averages show 'Sell' or 'Strong Sell' signals, while volatility is moderate. Technically, safe short-term buying is not advised until price gives a strong close above ₹830–₹845 (20/50 DMA zone) with improving volume and momentum indicators. For long-term accumulation, buying closer to ₹800 or lower (major supports) with strict risk management could be considered, but only in a phased manner and after signs of trend reversal.

Recent Result (Q2FY26) Analysis Natco’s Q2 showed revenue stability but declining profitability—impacted by business provisions, higher R&D spend, bonuses, and softer export demand. Margins were squeezed and profit after tax took a notable hit despite stable core business. This led to immediate stock price weakness and heavy market caution, further confirmed by technical weakness. Key Technical Levels & Buy Zones For short-term trading, avoid fresh buys until price closes decisively above ₹830–₹845 (20/50 DMA zone) on high volume. For long-term investors, phased buying can be planned near ₹800–₹780 with strict stop loss below ₹760, only if signs of reversal or accumulation emerge. Strong resistance is at ₹850–₹900, which must be watched for breakout confirmation. Sustainable bullish moves require reversal in technical indicators and fundamental improvement to support long-term upside.